



ISPOR Russia HTA Chapter Annual Report 2013

TO:

Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
505 Lawrence Square Blvd. South
Lawrenceville, NJ 08648, USA

PREPARED BY:

Vitaly Omelianovskiy, MD, PhD, DSc, Professor
Director of the Center for Health Technology Assessment of the Presidential Academy of
National Economy and Public Administration
ISPOR Russia HTA Chapter
Moscow, Russia
Tel: (+7-916-442-4139)
Email: vvo@hta-rus.ru, maksimova@hta-rus.ru

Background:

The ISPOR Russia HTA Chapter was approved in April 2011. The chapter has 200 members.
The current leadership of the ISPOR Russia HTA Chapter is comprised of the following:

President

Vitaly Omelianovsky, MD, PhD, DSc, Professor

Director of the Center for Health Technology Assessment of the Presidential
Academy of National Economy and Public Administration

Vice President

Maria Avxentyeva MD, PhD, DSc, Professor

Deputy Director of the Center for Health Technology Assessment of the
Presidential Academy of National Economy and Public Administration

Executive Director

Ludmila Maksimova, PhD, Head International Cooperation and External
Affairs of the Center for Health Technology Assessment of the Presidential
Academy of National Economy and Public Administration

For more information on the ISPOR Russia HTA Chapter, please visit the ISPOR Regional Chapter website:
http://www.ispor.org/regional_chapters/Russia-HTA/index.asp and
www.hta-rus.ru

Enclosure: ISPOR Russia HTA Chapter Annual Report 2013.

ISPOR Russia HTA Chapter Annual Report

The ISPOR Russia HTA Chapter has successfully developed or facilitated the following activities:

SCIENTIFIC /EDUCATIONAL ACTIVITIES:

1. Publications:

The Chapter members published 46 scientific articles in professional journals:

1. Omelyanovsky V. V., Fedyaeva V. K.

Analysis of the Additional Costs Associated with the Specific Conditions of Transportation and Storage of Antiretroviral Therapy Lopinavir + Ritonovir Formulations. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

2. Avxentyeva M. V., Omelyanovsky V. V., Gerasimova K. V.

Economic Analysis of Romiplostim (Nplate) for Treatment of Adults with Chronic Immune Thrombocytopenia in Russia. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

3. Sura M. V., Omelyanovsky V. V., Margieva A. V.

Standardization of the Procedure for Evaluating Formulary Drug Lists Using Automated Systems. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

4. Ivahnenko O. L., Avxentyeva M. V., Maxinova L. V.

Methods for Estimating Indirect Costs in Health Technology Assessment. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

5. Simonov A. N., Rebrova O. Yu.

Confidence Bootstrap Intervals for Clinical Economical Estimates. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

6. Yarovoy S. K., Avxentyeva M. V., Moskalyeva N. G., Romazanov E. Ya.

Clinical and Economic Aspects of Early Diagnostics and Radical Treatment of Prostate Cancer. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

7. Oskina Ye. A., Sirotko I.I.

Outcome of ABC- and VEN-analyses of Drug Consumption at the Regional Level. *Medical Technologies. Assessment and Selection*, 2013, #1(11).

8. Omelyanovsky V. V.

Market Access: Main Features and Definition. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

9. Kulinchik T. V.

Cisplatin: Discovery of Antitumor Activity. *Medical Technologies: Assessment and Selection*, 2013, #1(11).

10. Goryaynov S.V., Avxentyeva M.V.

Economic Analysis of Protease Inhibitors in Combination with NRTIS in Treatment-Naïve Adult Patients with HIV. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

11. Ivahnenko O.I., Omelyanovsky V.V., Khachatryan G.R., Rebrova O.Yu., Nikitin I.G.

Clinical and Economic Evaluation of Alternative Methods of Administering a Second Course of Antiviral Therapy to Patients with Genotype 1 Chronic Hepatitis. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

12. Khachatryan G.R., Skipenko O.G.

Analytical Report on Recent Trials Evaluating Technologies in Abdominal Surgery. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

13. Khan N.V.

Estimating the Amount of Specialized Medical Care Required for Patients with Acute Coronary Syndrome. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

14. Omelyanovsky V.V.

The Main Differences between Medical Devices and Pharmaceuticals and Distinctive Features of Their Research. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

15. Kozlov R.S., Omelyanovsky V.V., Sidorenko S.V., Khachatryan N.N., Yakovlev S.V.

Strategic Planning Workshop “Bacterial Resistance and Antimicrobial Therapy: Models and a Systemic Solution to the Problem”. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

16. Sura M.V., Maximova L.V., Nazarov V.S.

Price Regulation and Compensation Policies in the System for the Supply of Ambulatory Medications in Different Countries. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

17. Opimakh I.V.

Rosalind Franklin – the DNA Lady. *Medical Technologies. Assessment and Selection*, 2013, #2(12).

18. Omelyanovsky V.V.

Models for Organizing HTA in the Context of the Russian Health Care. *Medical Technologies. Assessment and Selection*, 2013, #3(13).

19. Simonov A.N., Miroshnichenko I.I., Rebrova O.Yu.

Construction Bootstrap Confidence Intervals of the Pharmacoeconomic Parameters. *Medical Technologies. Assessment and Selection*, 2013, #3(13).

20. Derkach E.V., Avxentyeva M.V., Rebrova O. Yu., Shifman E.M., Ignatyeva V.I., Nikolaenko E.M.

Clinical and Economic Assessment of Sugammadex (Bridion) in Reversing Neuromuscular Blockade during Surgical Interventions. *Medical Technologies. Assessment and Selection*, 2013, #3(13).

21. Kolyasnikova N.M., Avxentyev N.A., Avxentyeva M.V., Derkach E.V., Platonov A.E.

The Social and Economic Burden of Tick-Borne Encephalitis in the Russian Federation. *Medical Technologies. Assessment and Selection*, 2013, #3(13).

22. Zorin N.A.

Scientometrics – Mirror of Science. *Medical Technologies. Assessment and Selection*, 2013, #3(13).

23. Opimach I.V.

The Invention of Soap. *Medical Technologies. Assessment and Selection*, 2013, #3(13).

24. Avxentyeva M.V.

Cost-minimization Analysis of Dienogest Versus Gonadotrophin-releasing Hormone Analogues or Dydrogesterone for Endometriosis Treatment in Russia. *Value in Health* November 2013 Vol. 16, Issue 7, Page A334.

25. Avxentyeva M.A., Goryaynov S. V., Rebrova O.Yu.

Economic Analysis of Protease Inhibitors in First-Line Haart in Adult Patients with HIV. *Value in Health* November 2013, Vol. 16, Issue 7, Pages A356-A357.

26. Ignatyeva V. I, S. V. Goryaynov, M. V. Avxentyeva.

Budget Impact Analysis of Biologic Drugs for Treatment of Polyarticular Juvenile Rheumatoid Arthritis in Russia. *Value in Health* November 2013, Vol. 16, Issue 7, Page A559.

27. Ignatyeva V. I., M.Avxentyeva, Omelyanovsky V. V., Galstyan G.R.

The Cost of Specialized Hospital Care for Patients with Diabetic Foot Ulcers in Russia. *Value in Health* November 2013, Vol. 16, Issue 7, Page A444.

28. E.V. Derkach, M.V.Avxentyeva, V.V. Omelyanovsky.

Potential Economic Impact of Using Sugammadex for the Routine Reversal of Neuromuscular Blockade in Russian Health Care Setting. *Value in Health* November 2013, Vol. 16, Issue 7, Pages A558-A559.

29. Avxentev N. A., Avxentyeva M. V., Platonov A., Kolyasnikova N., Gridneva K., Dolgin V., A. Titkov, Derkach E.V.

Evaluating Economic Burden of Tick-Borne Encephalitis. Evidence from Russia. *Value in Health*, November 2013, Vol. 16, Issue 7, Pages A347-A348.

30. O. Ivakhnenko, G. Khachatryan, M.Avxentyeva, O. Rebrova, A. Müller-York

Pharmacoeconomic Analysis of Ioversol Versus Iohexol for Diagnostic Procedures. *Value in Health*, November 2013 Vol. 16, Issue 7, Page A468.

31. O. Ivakhnenko, O. Rebrova, M.Avxentyeva, G. Khachatryan.

Three TNF-A-Inhibitors for Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. *Value in*

Health, November 2013, Vol. 16, Issue 7, Page A564.

32. K. Gerasimova, M.Avxentyeva, S. Goryaynov, O. Rebrova.

Pharmacoeconomic Analysis of Abatacept for Treatment of Adults with Rheumatoid Arthritis in Russia. Value in Health, November 2013, Vol. 16, Issue 7, Page A564.

33. E. Pyadushkina, V. Omelyanovsky, M. Avxentyeva, O. Rebrova, S. Goryaynov.

Cost-Minimization Analysis of Maraviroc Versus Darunavir/Raltegravir and Enfuvirtide for CCR5-Tropic Treatment-Experienced Patients with HIV Infection in Russia. Value in Health, November 2013, Vol. 16, Issue 7, Page A440.

34. E. Pyadushkina, V. Omelyanovsky, M.Avxentyeva, O. Rebrova, N. Andreeva.

Pharmacoeconomic Evaluation of the Fixed-Dose Combination of Abacavir/Lamivudine in the Antiretroviral Therapy of Naïve HIV Infected Patients in Russia. Value in Health, November 2013, Vol. 16, Issue 7, Pages A345-A346.

35. E. A. Pyadushkina, N.S. Andreeva, V.V. Omelyanovskiy, M.V. Avxentyeva, O.Yu. Rebrova.

Clinical and Economic Analysis of use of Kivexa in the first line antiretroviral therapy of HIV infection in Russia. Epidemiology and Infectious Diseases. Topical Issues, 2013, #3, p. 68-79.

36. Sura V. Maria, Omelyanovskiy V. Vitaly.

Dossier System as a Practical Tool for Compiling Reimbursement Lists. Value in Health. Regional Issues, Vol. 2, Number 2, September/October 2013. P 284 – 289. ISSN 2212-1099.

37. M.V. Sura.

Analysis of price regulation and reimbursement mechanisms in the out-patient prescription drug supply systems of European countries. Cypa M.B. Problems of Standardization in Health Care, №11-12, 2013. p. 59 – 67.

38. Ignatyeva V.I., Derkach E. V., Omelyanovsky V.V., Avksentyeva M.A.

Economic burden of malignant ovary tumors in the Russian Federation. Oncologic gynecology, 2013, #1, p. 29-34.

39. Ignatyeva V.I., Galstyan G. R., Avxentyeva M.V., Dedov I.I.

Clinical and economic analysis of the use of epidermal growth factor preparation (Eberprot-P) in patients with diabetic foot syndrome. Endocrinology surgery, 2013, #1, p. 4-15.

40. Galstyan G. R., Sergeeva S.V., Ignatyeva V.I., Avxentyeva M.V., Dedov I.I.

Clinical and economic justification of the cost of quota for treatment of patients with diabetic foot syndrome. Diabetes Mellitus, 2013 (3), p. 71-83.

41. I.E. Sapozhnikova, E.I. Tarlovskaya, M.V. Avxentyeva, A.V. Sanatova

Analysis of typical treatment algorithms in patients with Type 2 Diabetes Mellitus at out-patient level of health care provision. Problems of Standardization in Healthcare, 2013, #1-2, p. 43-49.

42. T.V. Kulinchik, O.Yu. Rebrova, A.V. Margieva, A.V.

Comparative clinical and economic analysis of preparations for primary prophylaxis of thrombotic complications after orthopedic surgeries. Bulletin of traumatology and orthopedics named after Y.Y. Priorov, 2013. # 2. p. 46-53.

43. K. V. Gerasimova, M.V. Avxentyeva, D.A. Sychev, A.O. Chikalo, E.V. Gavrisyuk, V.G. Kukes.

Clinical and economic analysis of application of pharmaco-genetic testing for personalizing dosage of indirect anticoagulant of Varfarin in clinical practice. Medical Genetics, 2013. Volume. 12, №#1, p. 36-39.

44. V. V. Omelyanovsky, M.V. Avxentyeva, O.I. Ivakhnenko, I.S. Krysanov, N.A. Zorin, P.M. Khailov.

Comparative clinical and economic analysis of medication treatment of patients with schizophrenia with the first and second generation antipsychotic preparations in tablet form. Social and Clinical Psychiatry, 2013, Volume. 23, # 2. p. 73-83.

45. K. Cpalka, O. Rebrova, R. Nowicki, L. Rutkowski.

On Designing of Flexible Neuro-Fuzzy Systems for Nonlinear Modeling. Intern. Journal of General Systems (IF 0.667), 42(6): 706-720 (2013), 22.05.2013, DOI: 10.1080/03081079.2013.798912.

46. Ivakhnenko O, Omelyanovsky VV, Rebrova O, Khachatryan G.

Comparative economic analysis of retreatment strategies for HCV genotype 1 patients in Russia. Value in Health, 2013, Vol. 16, Issue 7, Page A498.

2. Seminars and Trainings:

Educational seminars on evidence-based medicine and pharmacoeconomics were held in 9 Russian regions. Together with Market Access Consulting the Chapter conducted 10 trainings covering such topics as regional health programs in Russia, market access in healthcare, regional market access and GR in healthcare, drug supply under the new contract system, financing the Russian healthcare system.

3. Presentations and Participation in Round tables/Special Sessions at Major Medical Conferences and Congresses and Market Access events:

- Russia ISPOR HTA Chapter members made about 100 presentations at 50 major domestic and international health conferences and congresses in Russia and abroad, including:
 - 17th Russian Pediatrics Congress with international participation. Topical Problems in Pediatrics, Moscow, February 14-17, 2013.
 - The ISPOR 18th Annual International Meeting in New Orleans, LA, USA May 18-22, 2013
 - The 8th All Russia Medical Forum, St. Petersburg, 10.10.2013, Nizhny Novgorod, 10.25.2013;
 - The 7th Scientific Congress “Rational Pharmacotherapy 2013”, St. Petersburg, September 10-12, 2013;
 - The 20th Russian National Congress “Man and Drug”, Moscow, April 15-19, 2013;
 - International forum Europe and Russia. Международный форум. Development Vector: Harmonization (3rd Session) Kazan, September 25, 2013;
 - The 16th ISPOR Annual European Congress in Dublin, Ireland, November 2-6, 2013;
 - Belarus Republican International Seminar “Bio-therapeutic drugs in the current health care practice”, April 26, 2013.
 - The 8th International Congress Rational Pharmacotherapy 2013, St. Petersburg, October 10-11, 2013;
 - Russia Federation Conference: Scientific and practical aspects of contemporary oncology, Krasnoyarsk, October 31, 2013.
 - International Scientific and Practical Congress Diabetes Mellitus and Surgical Infections. Moscow, October 14-17, 2013.
 - Meeting of the Expert Board on Healthcare of the Federation Council, Moscow, October 31, 2013;
 - Pseudo science in contemporary world: media sphere, higher education, and school. St. Petersburg, June 21-22, 2013;
 - The 12th International Conference on Artificial Intelligence and Soft Computing ICAISC 2013, Zakopane, Poland, June 9-13, 2013;
 - "5th Annual Russian & CEE Pharma Market Access Summit" and "3rd Annual Russian & CEE Device Market Access Summit" in Vienna, March 2013.
 - The Emerging Market Access Conference within the framework of Innovation Days in Paris, October 9, 2013.
2. **Pharmacoeconomic studies:** ISPOR Russia HTA Chapter completed 13 pharmacoeconomic and health economics studies covering multiple therapeutic areas, compounds and indications.

3. Development of HTA approaches

Toolkits for assessing and compiling formularies/reimbursed drug lists, including:

- a. **ABC/VEN/DDD analysis** – IT-based technology for evaluating hospital and regional government costs of drug purchases, assessing drug lists to confirm that drugs included in these lists are essential and vital. More than 280 Russian pharmacists, clinical pharmacologists, federal and regional health care decision-makers use ABC/VEN/DDD analysis program in their every day work.
- b. **PHARMEC** – a multi-level and interdisciplinary expert assessment of pharmaceuticals to provide support in developing reimbursement programs for regional health authorities.
- c. **Dossier program (www.docie.ru)** – a web-based value dossier preparation and submission

toolkit for developing regional reimbursed drug lists and hospital formularies. It is based on online application procedure (application form includes 30 different items) and availability of electronic reference database of drugs already included in reimbursement and under review.

4. ISPOR Russia HTA Chapter members actively participated in the ISPOR 16th European Congress on 2-6 November 2013 in Dublin (Ireland) with the following 13 poster presentations:

- 1) THREE TNF- α -INHIBITORS FOR TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS

Ivakhnenko O, Rebrova O, Avxentyeva M, **Khachatryan G**

- 2) COMPARATIVE ECONOMIC ANALYSIS OF RETREATMENT STRATEGIES FOR HCV GENOTYPE 1 PATIENTS IN RUSSIA

Ivakhnenko O, **Omelyanovsky VV**, Rebrova O, Khachatryan G

- 3) PHARMACOECONOMIC ANALYSIS OF IOVERSOL VS IOHEXOL FOR DIAGNOSTIC OR SURGICAL PROCEDURES

Ivakhnenko O, **Khachatryan G**, Avxentyeva M, Rebrova O, Müller-York A

- 4) BUDGET IMPACT ANALYSIS OF BIOLOGIC DRUGS FOR TREATMENT OF POLIARTICULAR JUVENILE RHEUMATOID ARTHRITIS IN RUSSIA

V.I. Ignatyeva , S.V. Goryainov, M.V. Avxentyeva

- 5) COST-EFFECTIVENESS OF INTRALESIONAL INJECTION OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR FOR THE TREATMENT OF SEVERE DIABETIC FOOT ULCERS IN RUSSIAN HEALTH CARE SETTING

V.I. Ignatyeva, M.V. Avxentyeva, G.R. Galstyan

- 6) THE COST OF SPECIALIZED HOSPITAL CARE FOR PATIENTS WITH DIABETIC FOOT ULCERS IN RUSSIA

Ignatyeva V. I, Avxentyeva M.V., V.V. Omelyanovsky, G.R. Galstyan

- 7) PHARMACOECONOMIC EVALUATION OF THE FIXED-DOSE COMBINATION OF ABACAVIR/LAMIVUDINE IN THE ANTIRETROVIRAL THERAPY OF NAïVE HIV INFECTED PATIENTS IN RUSSIA

Pyadushkina E., Omelyanovskiy V., Avxentyeva M., Rebrova O., Andreeva N.

- 8) COST-MINIMIZATION ANALYSIS OF MARAVIROC VERSUS DARUNAVIR RALTEGRAVIR AND ENFUVIRTIDE FOR CCR5-TROPIC TREATMENT-EXPERIENCED PATIENTS WITH HIV INFECTION IN RUSSIA

Pyadushkina E., Omelyanovsky V, Avxentyeva M, Rebrova O, Goryaynov S

- 9) POTENTIAL ECONOMIC IMPACT OF USING SUGAMMADEX FOR THE ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN RUSSIAN HEALTH CARE SETTING

Derkach E., **Avxentyeva M.**, **Omelyanovsky V.**

- 10) EVALUATING ECONOMIC BURDEN OF TICK-BORNE ENCEPHALITIS. EVIDENCE FROM RUSSIA

Avxentyeva M, **Avxentev N**, Platonov A, Kolyasnikova N, Gridneva K, Dolgin V

Titkov A, Derkach E

- 11) PHARMACOECONOMIC ANALYSIS OF ABATACEPT FOR TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS IN RUSSIA

Gerasimova K., Avxentyeva M., Goryaynov S., Rebrova O.

- 12) ECONOMIC ANALYSIS OF PROTEASE INHIBITORS IN FIRST-LINE HAART IN ADULT PATIENTS WITH HIV

Avxentyeva M., Goryaynov S., Rebrova O.

5. 13) COSTS ASSOCIATED WITH COLD CHAIN USED TO STORE AND TRANSPORT THERMALLY UNSTABLE ANTIRETROVIRAL DRUGS

Omelyanovsky VV; **Fedyaeva VK**

6. Participation in ISPOR short courses

More than 40 ISPOR Russia HTA Chapter members participated in 6 different short courses organized within the

framework of the 16th ISPOR Annual European ISPOR Congress on 2-6 November 2013 in Dublin (Ireland)

POLICY-RELATED ACTIVITIES:

ISPOR Russia HTA Chapter participated in the following projects funded by international financial organizations and Russian government:

- **Pilot project with the World Bank and the Federal Mandatory Insurance Fund on introducing hospital funding system based on DRG in three regions of Russia**
- **Clinical and Economic justification of implementing drug reimbursement system modifying the course of diseases at out-patient level**
- **Analysis of funding sources for new technologies in healthcare**

ISPOR Russia HTA Chapter together with the Council of Federation organized 12 meetings on different aspects of HTA in a number of important therapeutic areas, including 4 meetings in Moscow (including one high level meeting on introducing HTA in Russia organized by the Expert Board at the Speaker of the Federation Council V. I. Matvienko) and 8 meetings in various Russian regions (Yekaterinburg, Samara, Rostov-on-Don, Astrakhan, St Petersburg, Ufa, Tyumen).

CHAPTER MEETINGS and WORKSHOPS:

ISPOR Russia HTA Chapter President V. Omelyanovsky made presentations at three meetings at the ISPOR 18th Annual meeting in New Orleans in May 2013, including Board, CEE network and BRICs meetings. ISPOR Russia organized three meetings at the 16th Annual European Congress in Dublin, November 2-6, 2013:

- Conjoint Forum **NEW HEALTH REFORMS AND HTA STATUS IN RUSSIA, UKRAINE, BELARUS, KAZAKHSTAN, AND ARMENIA**, November 4, 2013.
- Roundtable **HOW CAN PHARMA INDUSTRY BENEFIT FROM AND LEVERAGE POPULATION AND PATIENT DATA WITH LOCAL AUTHORITIES?** November 4, 2013.
- Roundtable **WAYS TO OPTIMIZE PUBLIC FUNDING FOR DRUG AVAILABILITY UNDER PRESENT CONDITIONS**, November 5, 2013.

MEMBERSHIP DEVELOPMENT:

ISPOR Russia HTA Chapter has added 20 members since the end of 2012. The total number of Chapter members is over 200.

Upcoming Activities for ISPOR Russia HTA Chapter 2014

Tentative Agenda

Date	Activities
February	Special Session Rational pharmacotherapy and HTA within the framework of CIS Pharmaceutical Forum, Moscow, February 11-13, 2014
March	Training on Pharmacoeconomics and Market Access for representatives of Pharmaceutical companies, expert community and health administrators
May	Develop guidelines on EBM and PE
April	Internal chapter meetings, Moscow.
May	Chapter leadership elections

May-June	Participating in meetings within the framework of the ISPOR Annual meeting in Montreal
September	Training on HTA principles, Canadian HTA experience and modeling together with Canadian colleagues from PE Unit, Cancer Care Ontario
November	Co-organizing an HTA conjoint forum during with CEE network during the 17 th ISPOR Annual European Meeting, Amsterdam, Netherlands
February – December	Evidence-based medicine, Pharmacoeconomics and HTA Trainings for Russian regional health care officials and experts
February –June	Implementing HTA Elements on the federal and regional levels. Organizing meetings with regional ministers of Health in order to promote and implement HTA in Russia's regions.
February-December	Trainings for the staff of the regional ministries of health on implementing elements of HTA in their respective regions.